Management of patients with HER2-positive metastatic breast cancer is there an optimal sequence of HER2-directed approaches?

Cancer

Volumn 121, Issue 1, 2015, Pages 17-24

  Zelnak, Amelia B ^a   Wisinski, Kari B ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Breast; Cancer; Human epidermal growth factor receptor 2 (HER2) positive; Metastatic; Therapy

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; AFATINIB; ANASTROZOLE; BUPARLISIB; CAPECITABINE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EVEROLIMUS; LAPATINIB; LETROZOLE; LIVER ENZYME; NAVELBINE; NERATINIB; PACLITAXEL; PERTUZUMAB; PLACEBO; PROGESTERONE RECEPTOR; TAXANE DERIVATIVE; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; BREAST METASTASIS; CANCER INHIBITION; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; DIARRHEA; DRUG POTENTIATION; DRUG RESEARCH; DRUG TARGETING; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HUMAN; INJECTION SITE REACTION; MONOTHERAPY; NAUSEA; OVERALL SURVIVAL; PATIENT CARE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN SYNTHESIS INHIBITION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CLINICAL TRIAL (TOPIC); DNA SEQUENCE; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENETICS; METASTASIS;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; NEOPLASM METASTASIS; RECEPTOR, ERBB-2; SEQUENCE ANALYSIS, DNA;

EID: 84919342671     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28815     Document Type: Review

References (49)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30.
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177-182.
3. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med. 2007;357:39-51.
4. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
5. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:719-726.
6. Andersson M, Lidbrink E, Bjerre K, et al. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. J Clin Oncol. 2011;29:264-271.
7. Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastro-zole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol. 2009;27:5529-5537.
8. von Minckwitz G, Schwedler K, Schmidt M, et al; GBG 26/BIG 03-05 study group and participating investigators. Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. Eur J Cancer. 2011;47:2273-2281.
9. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355: 2733-2743.
10. Gelmon KA, Boyle F, Kaufman B, et al. Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER21 metastatic breast cancer: interim analysis (IA) of NCIC CTG MA. 31/GSK EGF 108919. Presented at: 2012 American Society of Clinical Oncology Annual Meeting; June 1-5, 2012; Chicago, IL.
11. Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010;28:1124-1130.
12. Blackwell KL, Burstein HJ, Storniolo AM, et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol. 2012;30:2585-2592.
13. Perez EA, Koehler M, Byrne J, Preston AJ, Rappold E, Ewer MS. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc. 2008;83:679-686.
14. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell. 2004;5:317-328.
15. Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M. Strongly enhanced antitumor activity of trastuzumab and pertu-zumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res. 2009;69:9330-9336.
16. Cortes J, Fumoleau P, Bianchi GV, et al. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2012;30:1594-1600.
17. Baselga J, Gelmon KA, Verma S, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol. 2010;28:1138-1144.
18. Baselga J, Cortes J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366: 109-119.
19. Swain SM, Kim SB, Cortes J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013;14:461-471.
20. Gil E, Brufsky A, Im Y, et al. Efficacy and safety of first-line (1L) pertuzumab (P), trastuzumab (T), and docetaxel (D) in HER2-positive MBC (CLEOPATRA) in patients previously exposed to trastuzumab. Presented at: 2013 Annual Meeting of the American Society of Clinical Oncology, May 31-June 4, 2013; Chicago, IL.
21. National Comprehensive Cancer Network. National Comprehensive Cancer Network Guidelines. Version 3. 2014. Fort Washington, PA: National Comprehensive Cancer Network; 2014.
22. Lewis Phillips GD, Li G, Dugger DL, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008;68:9280-9290.
23. Junttila TT, Li G, Parsons K, Phillips GL, Sliwkowski MX. Trastu-zumab-DM1 (T-DM1) retains all the mechanisms of action of tras-tuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat. 2011;128:347-356.
24. Burris HA 3rd, Rugo HS, Vukelja SJ, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol. 2011;29: 398-405.
25. Krop IE, LoRusso P, Miller KD, et al. A phase II study of trastuzu-mab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2012;30:3234-3241.
26. Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367: 1783-1791.
27. Krop IE, Kim SB, Gonzalez-Martin A, et al; on behalf of the TH3RESA study collaborators. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial [published online ahead of print May 1, 2014]. Lancet Oncol. doi: 10.1016/S1470-204570178-0.
28. Hurvitz SA, Dirix L, Kocsis J, et al. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2013;31:1157-1163.
29. Johnston S, Pippen J Jr, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for post-menopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol. 2009;27:5538-5546.
30. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Central Nervous System. nccn.org/professionals/physician-gls/pdf/cns.pdf 2013. Accessed July 2014.
31. Datko F, D'Andrea G, Dickler M, et al. Phase II study of pertuzu-mab, trastuzumab, and weekly paclitaxel in patients with metastatic HER2-overexpressing metastatic breast cancer. Cancer Res. 2012; doi: 10.1158/0008-5472.SABCS12-P5-18-20.
32. Yardley DA, Burris HA 3rd, Hanson S, et al. Weekly gemcitabine and trastuzumab in the treatment of patients with HER2-overexpressing metastatic breast cancer. Clin Breast Cancer. 2009;9: 178-183.
33. Burstein HJ, Keshaviah A, Baron AD, et al. Trastuzumab plus vinor-elbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer. 2007;110:965-972.
34. Bartsch R, Wenzel C, Altorjai G, et al. Capecitabine and trastuzu-mab in heavily pretreated metastatic breast cancer. J Clin Oncol. 2007;25:3853-3858.
35. Schaller G, Fuchs I, Gonsch T, et al. Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 over-expressing metastatic breast cancer pretreated with anthracyclines or taxanes. J Clin Oncol. 2007;25:3246-3250.
36. Burstein HJ, Sun Y, Dirix LY, et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol. 2010;28:1301-1307.
37. Martin M, Bonneterre J, Geyer CE Jr, et al. A phase 2 randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER21 advanced breast cancer. Eur J Cancer. 2013;49:3763-3772.
38. Lin NU, Winer EP, Wheatley D, et al. A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzu-mab. Breast Cancer Res Treat. 2012;133:1057-1065.
39. Awada A, Dirix L, Manso Sanchez L, et al. Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy. Ann Oncol. 2013;24:109-116.
40. Jankowitz RC, Abraham J, Tan AR, et al. Safety and efficacy of ner-atinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2-positive breast cancer: an NSABP Foundation Research Program phase I study. Cancer Chemother Pharmacol. 2013;72:1205-1212.
41. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61-70.
42. Berns K, Horlings HM, Hennessy BT, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 2007;12:395-402.
43. Eichhorn PJ, Gili M, Scaltriti M, et al. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res. 2008;68:9221-9230.
44. Hurvitz SA, Dalenc F, Campone M, et al. A phase 2 study of evero-limus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy. Breast Cancer Res Treat. 2013; 141:437-446.
45. Andre F, Campone M, O'Regan R, et al. Phase I study of everoli-mus plus weekly paclitaxel and trastuzumab in patients with meta-static breast cancer pretreated with trastuzumab. J Clin Oncol. 2010; 28:5110-5115.
46. Andre F, O'Regan R, Ozguroglu M, et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2014;15:580-591.
47. Hudis C, Swanton C, Janjigian YY, et al. A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and tras-tuzumab in patients with HER2-positive solid tumors. Breast Cancer Res. 2013;15:R110.
48. Saura C, Bendell J, Jerusalem G, et al. Phase Ib study of buparlisib plus trastuzumab in patients with HER2-positive advanced or meta-static breast cancer that has progressed on trastuzumab-based therapy. Clin Cancer Res. 2014;20:1935-1945.
49. Perez EA, Spano JP. Current and emerging targeted therapies for metastatic breast cancer. Cancer. 2012;118:3014-3025.